The development of STING agonists for cancer has been beset by safety issues and discontinued programmes, but Daiichi Sankyo is hoping a new antibody-drug conjugate (ADC) could succeed where others ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will receive ...

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...